Meta-analysis shows endocrine therapies affect bone mineral density and fracture risk in postmenopausal breast cancer patients, suggesting careful therapy selection.
Key Points
Aromatase inhibitors significantly reduced bone mineral density and increased fracture risk.
Pooled odds ratio showed fracture risk increased statistically in the experimental group at 1.40.
Meta-analysis performed on randomized controlled trials identified critical differences among therapies.
Findings highlight the need for greater attention to bone health in endocrine therapy decisions.